Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 20/20 | 0.64 |
| ▸ | F2 | P00734 | 2/20 | 0.62 |
| ▸ | CTSG | P08311 | 2/20 | 0.62 |
| ▸ | CTRC | Q99895 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6456298 | 0.95 | CMA1 (0.59) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL6471076 | 0.89 | CMA1 (0.51) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL6479891 | 0.83 | CMA1 (0.51) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL5620407 | 0.78 | CMA1 (1.00) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL6456450 | 0.72 | CMA1 (0.85) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL6459484 | 0.71 | CMA1 (0.88) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL10967564 | 0.68 | CMA1 (0.50) | CMA1 | |
| SCHEMBL6453073 | 0.68 | CMA1 (1.00) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL6471075 | 0.65 | CMA1 (0.77) | CMA1F2CTSGCTRCPRSS1 | |
| SCHEMBL6438726 | 0.65 | CMA1 (0.82) | CMA1F2CTSGPRSS1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | CMA1 3/4885F2 3536/4885CTSG 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.